高级检索
当前位置: 首页 > 详情页

Transcription co-activator P300 activates Elk1-aPKC-ι signaling mediated epithelial-to-mesenchymal transition and malignancy in hepatocellular carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Dept Biliary & Pancreat Surg,Canc Res Ctr,Tongji Hosp,Tongji Med Coll,Wuhan 430030,Peoples R China [2]Shandong Acad Med Sci, Inst Basic Med, Jinan 250000, Peoples R China [3]Hainan Med Univ, Dept Hepatopancreatobiliary Surg, Affiliated Hosp 1, Haikou 570102, Hainan, Peoples R China [4]Wuhan Univ Sci & Technol, Dept Hepatobiliary Pancreat Surg, Affiliated Tianyou Hosp, Wuhan 430064, Peoples R China
出处:
ISSN:

摘要:
Epithelial-to-mesenchymal transition (EMT) plays an important role in invasion and metastasis of hepatocellular carcinoma (HCC). Our previous study found that atypical protein kinase C-iota (aPKC-iota) promoted the EMT process in HCC. However, how the aPKC-iota signaling pathway is regulated in HCC has not been elucidated. In this study, vector transfection was utilized to study the invasion of HCC cells, and the mechanism between P300 and aPKC-iota signaling pathways in regulating the EMT process of HCC was further elucidated in vitro and in vivo. We found both P300 and aPKC-iota were highly expressed in HCC and they were correlated with tumor progression and poor survival in HCC patients. P300 knockdown inhibited EMT, invasion and other malignant events of HCC cells but promoted cell apoptosis and cycle arrest. However, the effects mediated by P300 knockdown were abolished by aPKC-iota overexpression. Further studies showed that P300 upregulates aPKC-iota expression through increasing the transcription of Elk1, a transcriptional activator of aPKC-iota, and stabilizing Elk1 protein and its phosphorylation. In conclusion, our work uncovered the molecular mechanism by which oncogenic aPKC-iota is upregulated in HCC and suggests that P300, like aPKC-iota, may be used as a prognostic biomarker and therapeutic target in patients with HCC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Dept Biliary & Pancreat Surg,Canc Res Ctr,Tongji Hosp,Tongji Med Coll,Wuhan 430030,Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol,Dept Biliary & Pancreat Surg,Canc Res Ctr,Tongji Hosp,Tongji Med Coll,Wuhan 430030,Peoples R China [4]Wuhan Univ Sci & Technol, Dept Hepatobiliary Pancreat Surg, Affiliated Tianyou Hosp, Wuhan 430064, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:1 总访问量:411 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)